Bioventus Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (L
Consolidated Statements of Operations and Comprehensive Income (Loss)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Net sales | $568,087 | $573,280 | $512,345 |
| Cost of sales (including depreciation and amortization of $41,251, $41,882 and $48,503, respectively) | 179,930 | 185,054 | 184,152 |
| Gross profit | 388,157 | 388,226 | 328,193 |
| Selling, general and administrative expense | 314,026 | 343,798 | 303,879 |
| Research and development expense | 12,113 | 13,951 | 13,446 |
| Restructuring costs | 2,235 | (52) | 840 |
| Change in fair value of contingent consideration | — | 1,423 | 719 |
| Depreciation and amortization | 5,727 | 7,652 | 8,842 |
| Impairment of assets | — | 36,357 | 78,615 |
| Loss on disposals | 81 | 292 | 3,577 |
| Operating income (loss) | 53,975 | (15,195) | (81,725) |
| Interest expense, net | 26,486 | 38,792 | 40,676 |
| Loss on extinguishment | 326 | — | — |
| Other expense (income) | 1,454 | (1,645) | (1,290) |
| Other expense | 28,266 | 37,147 | 39,386 |
| Income (loss) before income taxes | 25,709 | (52,342) | (121,111) |
| Income tax (benefit) expense, net | (1,565) | (5,293) | 85 |
| Net income (loss) from continuing operations | 27,274 | (47,049) | (121,196) |
| Loss from discontinued operations, net of tax | — | — | (74,429) |
| Net income (loss) | 27,274 | (47,049) | (195,625) |
| (Income) loss attributable to noncontrolling interest - continuing operations | (4,542) | 10,924 | 24,458 |
| Loss attributable to noncontrolling interest - discontinued operations | — | — | 14,937 |
| Net income (loss) attributable to Bioventus Inc. | $22,732 | $(36,125) | $(156,230) |
| Net income (loss) | $27,274 | $(47,049) | $(195,625) |
| Other comprehensive income (loss), net of tax | |||
| Change in prior service cost and unrecognized gain (loss) for defined benefit plan adjustment | 21 | 13 | (8) |
| Change in foreign currency translation adjustments | 1,806 | (4,194) | 1,140 |
| Change in the fair value of cash flow hedges | (991) | — | — |
| Comprehensive income (loss) | 28,110 | (51,230) | (194,493) |
| Comprehensive (income) loss attributable to noncontrolling interest - continuing operations | (4,705) | 11,738 | 24,230 |
| Comprehensive loss attributable to noncontrolling interest - discontinued operations | — | — | 14,937 |
| Comprehensive income (loss) attributable to Bioventus Inc. | $23,405 | $(39,492) | $(155,326) |
| Income (loss) per share of Class A common stock from: | |||
| Continuing operations—basic | $0.34 | $(0.56) | $(1.54) |
| Discontinued operations—basic | — | — | (0.95) |
| Basic income (loss) per Class A common stock | $0.34 | $(0.56) | $(2.49) |
| Continuing operations—diluted | $0.33 | $(0.56) | $(1.54) |
| Discontinued operations—diluted | — | — | (0.95) |
| Diluted income (loss) per Class A common stock | $0.33 | $(0.56) | $(2.49) |
| Weighted-average shares of Class A common stock outstanding: | |||
| Basic | 66,622,631 | 64,547,474 | 62,647,554 |
| Diluted | 68,914,895 | 64,547,474 | 62,647,554 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.